Synopsis: Nectar Lifesciences jumped sharply after the company announced that it would have a Board meeting on December 3, 2025, to consider a share buyback proposal.
The shares of this leading pharma company engaged in manufacturing APIs and Formulations are in focus after the company made a key announcement that fetched robust investor interest from the streets. In this article, we will dive more into the details of it.
With a market capitalisation of Rs 367 crore, the shares of Nectar Lifescience Ltd made a day high of Rs 16.99 per share (upper circuit), up by 20 percent from its previous day’s closing price of Rs 14.16 per share. Over the past five years, the stock has corrected by over 10 percent, underperforming NIFTY 50’s positive return of 102 percent.
About the Announcement
Nectar Lifesciences, through a stock exchange filing, announced that its Board of Directors will be meeting on December 3, 2025 (Wednesday), to consider a share buyback proposal.
A buyback generally signifies that the company sees its shares as being undervalued or wants to give back to shareholders by decreasing the number of shares available in the market. However, the additional details like the buyback price, size, and route, will only be clear after the Board’s decision at the next meeting.
Financial and Other Highlights
Nectar Lifescience reported a core revenue of Rs 5.87 crore in Q2 FY26, a decline of 13 percent as compared to Rs 6.71 crore in Q2 FY25. Additionally, it declined by 5 percent from Rs 6.15 crore in Q1 FY26.
Regarding its profitability, it reported a net loss of Rs 176 crore in Q2 FY26, a sharp turnaround as compared to a profit of Rs 6 crore in Q2 FY25. Additionally, on a QoQ basis, its losses widened from Rs 63 crore in Q1 FY26.
Nectar Lifesciences (NLL) is a pharmaceutical company based in India that produces medicines and their essential ingredients (APIs), primarily in the anti-infective segment. It has transformed itself from a mere small API maker into one of India’s top mid-sized pharma companies, thus being listed in the Fortune Next 500 and ranked among the leading bio-pharma players in the Asia-Pacific region.
The company is exporting its products to nearly 45 countries and has 13 state-of-the-art manufacturing units spread across Punjab and Himachal Pradesh, all of which have been established according to global quality and safety standards. Besides, NLL has a competent workforce and a subsidiary in Portugal, which makes its international presence even stronger.
Written by Satyajeet Mukherjee
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post 20% Upper Circuit: Pharma stock skyrockets after board to consider share buyback appeared first on Trade Brains.